Evidence of an anti-inflammatory effect of mycophenolate mofetil in a murine model of pleurisy

Experimental Lung Research

Volumn 37, Issue 7, 2011, Pages 399-407

  Monguilhott Dalmarco, Eduardo ^a   Mendes De Córdova, Caio Maurício ^a   Fröde, Tânia Silvia ^b  

^a REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anti inflammatory activity; Interleukin 17A, interleukin 1 ; Leukocyte influx; Mycophenolate mofetil; Tumor necrosis factor ; Vascular endothelial growth factor

Indexed keywords

CARRAGEENAN; DEXAMETHASONE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEURISY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CYTOKINES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; LEUKOCYTES; MICE; MYCOPHENOLIC ACID; PLEURISY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051729508     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2011.570416     Document Type: Article

References (25)

1. Calcagni E, Elenkov I: Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad Sci. 2006;1069:62-76.
2. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M: Immune response modifiers-mode of action. Exp Dermatol. 2006;15:331-341.
3. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S: The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol. 2008;20:1361-1368.
4. Stow JL, Ching Low P, Offenhäuser C, Sangermani D: Cytokine secretion in macrophages and other cells: Pathways and mediators. Immunobiology. 2009;214:601-614.
5. Villarroel MC, Hidalgo M, Jimeno A: Mycophenolate mofetil: An update. Drugs Today (Barc). 2009;45:521-532.
6. Zandman-Goddard G, Shoenfeld Y: Mycophenolate mofetil in animal models of autoimmune disease. Lupus. 2005;14:s12-s16.
7. Sahin GM, Sahin S, Kantarci G, Ergin H: Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton). 2007;12:285-288.
8. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N: Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972-980.
9. Buhaescu I, Covic A, Levy J: Systemic vasculitis: Still a challenging disease. Am J Kidney Dis. 2005;46:173-185.
10. Heatwole C, Ciafaloni E: Mycophenolate mofetil for myasthenia gravis: A clear and present controversy. Neuropsychiatr Dis Treat. 2008;4:1203-1209.
11. Antoniu SA: Treatment options for refractory Wegener's granulomatosis: A role for rituximab? Curr Opin Investig Drugs. 2007;8:927-932.
12. Saketkoo LA, Espinoza LR: Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med. 2008;168:1718-1719.
13. Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW: Mycophenolate mofetil in dermatology. J AmAcad Dermatol. 2009;60:183-199.
14. Saleh TS, Calixto JB, Medeiros YS: Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy. Br J Pharmacol. 1996;118:811-819.
15. Dalmarco EM, Fröde TS, Medeiros YS: Effects of methotrexate upon inflammatory parameters induced by carrageenan in the mouse model of pleurisy. Mediators Inflamm. 2002;11:299-306.
16. Dalmarco EM, Fröde TS, Medeiros YS: Additional evidence of acute anti-inflammatory effects of cyclosporin A in a murine model of pleurisy. Transpl Immunol. 2004;12:151-157.
17. Pereira R, Medeiros YS, Fröde TS: Antiinflammatory effects of Tacrolimus in a mouse model of pleurisy. Transpl Immunol. 2006;16:105-111.
18. Farivar AS, MacKinnon-Patterson B, Barnes AD, Mulligan MS: The effect of anti-inflammatory properties of mycophenolate mofetil on the development of lung reperfusion injury. J Heart Lung Transplant. 2005;24:2235-2242.
19. Saad SY, Arafah MM, Najjar TA: Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chemother Pharmacol. 2007;59:455-460.
20. Glomsda BA, Blaheta RA, Hailer NP: Inhibition of monocyte/ endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord. 2003;41:610-619.
21. Jonsson CA, Carlsten H: Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol. 2002;216:93-101.
22. Weimer R, Mytilineos J, Feustel A, Preiss A, Daniel V, Grimm H, Wiesel M, Opelz G:Mycophenolate mofetil-based immunosuppression and cytokine genotypes: Effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation. 2003;75:2090-2099.
23. Lee J, Kim MS, Kim EY, Park HJ, Chang CY, Park KS, Jung DY, Kwon CH, Joh JW, Kim SJ: Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis. Cytokine. 2008;44:49-56.
24. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B: Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol. 2007;293:616-623.
25. Von Vietinghoff S, Ouyang H, Ley K: Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int. 2010;78:79-88.